chr9-5073770-G-T

Variant summary

Our verdict is Pathogenic. The variant received 11 ACMG points: 11P and 0B. PM5PP3PP5_Very_Strong

The NM_004972.4(JAK2):​c.1849G>T​(p.Val617Phe) variant causes a missense change involving the alteration of a conserved nucleotide. The variant allele was found at a frequency of 0.000293 in 1,605,918 control chromosomes in the GnomAD database, including 17 homozygotes. There is a variant allele frequency bias in the population database for this variant (GnomAd4), which may indicate mosaicism or somatic mutations in the reference population data. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Likely pathogenic (★★). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. V617I) has been classified as Pathogenic.

Frequency

Genomes: 𝑓 0.00036 ( 1 hom., cov: 33)
Exomes 𝑓: 0.00029 ( 16 hom. )

Consequence

JAK2
NM_004972.4 missense

Scores

8
8
2

Clinical Significance

Pathogenic/Likely pathogenic criteria provided, multiple submitters, no conflicts P:26O:2

Conservation

PhyloP100: 9.55

Publications

2151 publications found
Variant links:
Genes affected
JAK2 (HGNC:6192): (Janus kinase 2) This gene encodes a non-receptor tyrosine kinase that plays a central role in cytokine and growth factor signalling. The primary isoform of this protein has an N-terminal FERM domain that is required for erythropoietin receptor association, an SH2 domain that binds STAT transcription factors, a pseudokinase domain and a C-terminal tyrosine kinase domain. Cytokine binding induces autophosphorylation and activation of this kinase. This kinase then recruits and phosphorylates signal transducer and activator of transcription (STAT) proteins. Growth factors like TGF-beta 1 also induce phosphorylation and activation of this kinase and translocation of downstream STAT proteins to the nucleus where they influence gene transcription. Mutations in this gene are associated with numerous inflammatory diseases and malignancies. This gene is a downstream target of the pleiotropic cytokine IL6 that is produced by B cells, T cells, dendritic cells and macrophages to produce an immune response or inflammation. Disregulation of the IL6/JAK2/STAT3 signalling pathways produces increased cellular proliferation and myeloproliferative neoplasms of hematopoietic stem cells. A nonsynonymous mutation in the pseudokinase domain of this gene disrupts the domains inhibitory effect and results in constitutive tyrosine phosphorylation activity and hypersensitivity to cytokine signalling. This gene and the IL6/JAK2/STAT3 signalling pathway is a therapeutic target for the treatment of excessive inflammatory responses to viral infections. Alternative splicing results in multiple transcript variants encoding distinct isoforms. [provided by RefSeq, Jul 2020]
INSL6 (HGNC:6089): (insulin like 6) The protein encoded by this gene contains a classical signature of the insulin superfamily and is significantly similar to relaxin and relaxin-like factor. This gene is preferentially expressed in testis. Its expression in testis is restricted to interstitial cells surrounding seminiferous tubules, which suggests a role in sperm development and fertilization. [provided by RefSeq, Jul 2008]

Genome browser will be placed here

ACMG classification

Classification was made for transcript

Our verdict: Pathogenic. The variant received 11 ACMG points.

PM5
Other missense variant is known to change same aminoacid residue: Variant chr9-5073770-G-A is described in ClinVar as Pathogenic. ClinVar VariationId is 29763.Status of the report is no_assertion_criteria_provided, 0 stars.
PP3
MetaRNN computational evidence supports a deleterious effect, 0.809
PP5
Variant 9-5073770-G-T is Pathogenic according to our data. Variant chr9-5073770-G-T is described in ClinVar as Pathogenic/Likely_pathogenic. ClinVar VariationId is 14662.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars.

Variant Effect in Transcripts

ACMG analysis was done for transcript: NM_004972.4. You can select a different transcript below to see updated ACMG assignments.

RefSeq Transcripts

Sel.
GeneTranscriptTagsHGVScHGVSpEffectExon RankProteinUniProt
JAK2
NM_004972.4
MANE Select
c.1849G>Tp.Val617Phe
missense
Exon 14 of 25NP_004963.1
JAK2
NM_001322194.2
c.1849G>Tp.Val617Phe
missense
Exon 14 of 25NP_001309123.1
JAK2
NM_001322195.2
c.1849G>Tp.Val617Phe
missense
Exon 13 of 24NP_001309124.1

Ensembl Transcripts

Sel.
GeneTranscriptTagsHGVScHGVSpEffectExon RankProteinUniProt
JAK2
ENST00000381652.4
TSL:1 MANE Select
c.1849G>Tp.Val617Phe
missense
Exon 14 of 25ENSP00000371067.4
JAK2
ENST00000870320.1
c.1849G>Tp.Val617Phe
missense
Exon 14 of 25ENSP00000540379.1
JAK2
ENST00000870321.1
c.1849G>Tp.Val617Phe
missense
Exon 14 of 25ENSP00000540380.1

Frequencies

GnomAD3 genomes
AF:
0.000362
AC:
55
AN:
151910
Hom.:
1
Cov.:
33
show subpopulations
Gnomad AFR
AF:
0.000363
Gnomad AMI
AF:
0.00
Gnomad AMR
AF:
0.00
Gnomad ASJ
AF:
0.000866
Gnomad EAS
AF:
0.000193
Gnomad SAS
AF:
0.000622
Gnomad FIN
AF:
0.000284
Gnomad MID
AF:
0.00
Gnomad NFE
AF:
0.000442
Gnomad OTH
AF:
0.00
GnomAD2 exomes
AF:
0.000352
AC:
88
AN:
250262
AF XY:
0.000333
show subpopulations
Gnomad AFR exome
AF:
0.000309
Gnomad AMR exome
AF:
0.000174
Gnomad ASJ exome
AF:
0.000597
Gnomad EAS exome
AF:
0.000163
Gnomad FIN exome
AF:
0.000561
Gnomad NFE exome
AF:
0.000397
Gnomad OTH exome
AF:
0.000164
GnomAD4 exome
AF:
0.000286
AC:
416
AN:
1454008
Hom.:
16
Cov.:
28
AF XY:
0.000343
AC XY:
248
AN XY:
723690
show subpopulations
African (AFR)
AF:
0.000120
AC:
4
AN:
33282
American (AMR)
AF:
0.000157
AC:
7
AN:
44662
Ashkenazi Jewish (ASJ)
AF:
0.000730
AC:
19
AN:
26024
East Asian (EAS)
AF:
0.000101
AC:
4
AN:
39580
South Asian (SAS)
AF:
0.000279
AC:
24
AN:
85974
European-Finnish (FIN)
AF:
0.000302
AC:
16
AN:
52968
Middle Eastern (MID)
AF:
0.000522
AC:
3
AN:
5746
European-Non Finnish (NFE)
AF:
0.000295
AC:
326
AN:
1105638
Other (OTH)
AF:
0.000216
AC:
13
AN:
60134
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.405
Heterozygous variant carriers
0
18
37
55
74
92
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Exome Het
Exome Hom
Variant carriers
0
20
40
60
80
100
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
GnomAD4 genome
AF:
0.000362
AC:
55
AN:
151910
Hom.:
1
Cov.:
33
AF XY:
0.000350
AC XY:
26
AN XY:
74238
show subpopulations
⚠️ The allele balance in gnomAD version 4 Genomes is significantly skewed from the expected value of 0.5.
African (AFR)
AF:
0.000363
AC:
15
AN:
41374
American (AMR)
AF:
0.00
AC:
0
AN:
15260
Ashkenazi Jewish (ASJ)
AF:
0.000866
AC:
3
AN:
3464
East Asian (EAS)
AF:
0.000193
AC:
1
AN:
5194
South Asian (SAS)
AF:
0.000622
AC:
3
AN:
4824
European-Finnish (FIN)
AF:
0.000284
AC:
3
AN:
10574
Middle Eastern (MID)
AF:
0.00
AC:
0
AN:
316
European-Non Finnish (NFE)
AF:
0.000442
AC:
30
AN:
67902
Other (OTH)
AF:
0.00
AC:
0
AN:
2090
⚠️ The allele balance in gnomAD version 4 Genomes is significantly skewed from the expected value of 0.5. (p-value = 0.00000141331), which strongly suggests a high chance of mosaicism in these individuals.
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.383
Heterozygous variant carriers
0
3
6
9
12
15
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Genome Het
Genome Hom
Variant carriers
0
2
4
6
8
10
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
Alfa
AF:
0.000348
Hom.:
14
ESP6500AA
AF:
0.000227
AC:
1
ESP6500EA
AF:
0.000233
AC:
2
ExAC
AF:
0.000692
AC:
84
EpiCase
AF:
0.0000546
EpiControl
AF:
0.000593

ClinVar

ClinVar submissions as Germline
Significance:Pathogenic/Likely pathogenic
Revision:criteria provided, multiple submitters, no conflicts
View on ClinVar
Pathogenic
VUS
Benign
Condition
8
-
-
not provided (8)
6
-
-
Acquired polycythemia vera (6)
3
-
-
Primary myelofibrosis (3)
2
-
-
Primary myelofibrosis;C0023467:Acute myeloid leukemia;C0032463:Acquired polycythemia vera;C0856761:Budd-Chiari syndrome;C3281125:Thrombocythemia 3;C4551637:Primary familial polycythemia due to EPO receptor mutation (2)
2
-
-
Thrombocythemia 3 (2)
1
-
-
Acute myeloid leukemia (1)
1
-
-
JAK2-related disorder (1)
1
-
-
Myeloproliferative disorder (1)
1
-
-
Polycythemia (1)
1
-
-
Primary myelofibrosis;C0038002:Splenomegaly (1)
-
-
-
Budd-Chiari syndrome, susceptibility to, somatic (1)
-
-
-
Primary familial polycythemia due to EPO receptor mutation (1)

Computational scores

Source: dbNSFP v4.9

Name
Calibrated prediction
Score
Prediction
AlphaMissense
Benign
0.33
BayesDel_addAF
Pathogenic
0.20
D
BayesDel_noAF
Pathogenic
0.36
CADD
Pathogenic
29
DANN
Uncertain
1.0
DEOGEN2
Pathogenic
0.85
D
Eigen
Pathogenic
0.85
Eigen_PC
Pathogenic
0.84
FATHMM_MKL
Uncertain
0.94
D
LIST_S2
Benign
0.77
T
M_CAP
Pathogenic
0.34
D
MetaRNN
Pathogenic
0.81
D
MetaSVM
Uncertain
0.44
D
MutationAssessor
Uncertain
2.1
M
PhyloP100
9.5
PrimateAI
Uncertain
0.70
T
PROVEAN
Uncertain
-3.9
D
REVEL
Pathogenic
0.88
Sift
Uncertain
0.0020
D
Sift4G
Uncertain
0.0070
D
Polyphen
1.0
D
Vest4
0.89
MVP
0.97
MPC
0.84
ClinPred
0.92
D
GERP RS
5.5
Varity_R
0.88
gMVP
0.72
Mutation Taster
=24/76
disease causing (ClinVar)

Splicing

Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
0.010
Details are displayed if max score is > 0.2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

Other links and lift over

dbSNP: rs77375493; hg19: chr9-5073770; COSMIC: COSV67569051; API